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more than one worker over four will spend one hour per day providing care to a 
patient with dementia. Increasing the proportion of treated patients may be a way 
to control costs and reduce burden on the society.
Mental HealtH – Patient-Reported Outcomes & Patient Preference Studies
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PRedictORS Of adHeRence tO antidePReSSant ÝMedicatiOnS in Saudi 
aRabia Ý
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Objectives: The aim of this study was to explore patients’ adherence to antidepres-
sant medication and predictors are associated with adherence, among patients diag-
nosed with depression in a psychiatric hospital in Riyadh , Saudi Arabia. MethOds: 
Non experimental cross-sectional design used to measure adherence to antide-
pressants among depressed patients and predictors are associated with adher-
ence, patients were recruit from outpatient clinic at AL-Amal hospital in Riyadh 
(psychiatric hospital) between August 2013 and January 2014. Results: A total of 
403 patients meet the inclusion criteria and were participated in this study. Two 
hundred three representing 50.37 % of the total study sample, were female, while the 
remaining 200 (49.6 %) were male, with average 39 years. 52.9% of the patients report 
low adherence to antidepressant medication with a statically significant different 
between low adherence and high adherence scour in female gender, younger age, 
patients with shorter duration of illness and have lees number of visit to outpa-
tient clinic. cOnclusiOns: Low adherence is a common health problem among 
depressed patients in Saudi Arabia, this study has improve understanding of adher-
ence predictors to antidepressant and their association, this understanding should 
help care giver and stakeholder to improve depressed patient management and 
clinical outcome by addressing medications taking behavior using a systematic 
approach based in this finding.
PMH26
GeneRal beliefS abOut MedicineS aMOnG dePReSSed PatientS in Saudi 
aRabia
Aljumah K.1, Hassali A.2
1MOH, Riyadh, Saudi Arabia, 2Universiti Sains Malaysia, Penang, Malaysia
Objectives: The aim of this study was to explore patients’ general and specific 
beliefs about medicines among depressed patients and effect on adherence and 
other clinical outcome in Saudi Arabia. MethOds: A cross-sectional design used 
to measure patients’ general and specific beliefs among depressed patients, using 
BMQ general and specific scales. Patients were recruit from outpatient clinic at 
AL-Amal hospital in Riyadh (psychiatric hospital). Results: A total of 403 patients 
meet the inclusion criteria and were participated in this study. Two hundred three 
representing 50.37 % of the total study sample, were female, while the remaining 
200 (49.6 %) were male, with average 39 years. 52.9% of patients report low adherence 
to antidepressant medication. Both low and high adherence group scored high in 
the necessity beliefs (18.02 (SD 3.91)-18.32 (SD3.9)respectively with no statistically 
different. contrariwise patients with high adherence had significantly lower level of 
concerns belief about antidepressants medication and less harmful belief also the 
same finding with general overuse belief. cOnclusiOns: General patients beliefs 
either general overuse or general harm about medication influence patients taking 
medication behavior and have negative correlation with adherence to medication on 
other hand only specific concerns belief to antidepressant have a positive correla-
tion with adherence to antidepressant this finding will help psychiatric to improve 
adherence and clinical outcome by addressing medications taking behavior using 
a systematic approach based in this finding.
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Objectives: The objective of this pilot study was to examine opioid analgesic (OA) 
use and patient reported outcomes (PRO) among opioid-dependent chronic nonma-
lignant pain (CNMP) patients placed on buprenorphine therapy in the Functional 
Restoration and Pain Management (FRPM) program. MethOds: A retrospective 
cohort analysis of administrative claims, medical records and responses to PRO 
questionnaires was conducted among Texas Workers Compensation (TWC) benefi-
ciaries enrolled in the FRPM program. Prescription utilization patterns, pain sever-
ity and self-report PROs were assessed during a 3-month observation period. PRO 
measures included the Visual Analogue Scale (VAS) for pain assessment, McGill Pain 
Questionnaire (MPQ), Beck Anxiety Inventory (BAI), and Beck Depression Inventory-II 
(BDI-II). Eligible patients were ≥ 18 years of age, opioid dependent, had a history 
of chronic pain medications, receiving buprenorphine therapy, and continuously 
enrolled in TWC benefit during the 3-month period. Results: The mean age of 
eligible study participants (N= 19) was 49.0 years ±7.6. A majority of patients were 
male (58%), white (63%), had a depression comorbidity (79%) and chronic pain lum-
bar diagnosis (47%). Overall, patients enrolled in the study showed a significant 
reduction in OA medication utilization (p< 0.01) at months 1 and 2-3 compared to 
baseline. For the PRO measures, a significant reduction in patient VAS pain scores 
was observed between baseline and month 1 (p= 0.03), no increases in pain scores 
were observed at months 2-3. Significant decreases in MPQ-A (p< 0.04) and BDI-II 
(p< 0.01) scores were observed between baseline and months 1 and 2-3. No dif-
ferences for BAI scores were observed. cOnclusiOns: Though a pilot study, the 
results suggest that opioid dependent patients receiving buprenorphine therapy in 
the FRPM program has the potential of improving health outcomes of patients with 
and only a small percentage of patients (23.7%) was first treated by mental health 
specialists. cOnclusiOns: The reported cost of managing MDD in China was high. 
Most patients first seek treatment in general medical clinics or hospitals instead 
of mental health specialists.
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Objectives: Various pharmacotherapy options are available for major depressive 
disorder (MDD) in China. However, the cost-effectiveness (CE) evaluations for these 
treatments are not systematically reported in English literature. A structured lit-
erature review was conducted to identify the health economics data of available 
treatment options in China. MethOds: A structured literature review on published 
articles in both English and Mandarin languages was conducted. Literature search 
was conducted using PubMed, Cochrane, WAN FANG, and VIP databases. Articles 
published between 2000 and 2013 were selected. The inclusion criteria included 
studies on Chinese population based in China only, as well as studies that reported 
cost effectiveness ratio (CER) or incremental cost effectiveness ratio (ICER) of MDD 
pharmacotherapy. Four reviewers (two for each language) independently selected, 
reviewed and extracted information from the articles. Results: 17 English & 63 
Mandarin articles were identified. None of the English articles and 23 Mandarin arti-
cles fulfilled the inclusion criteria. 17 of the 23 Mandarin articles analysed the CER 
or ICER of the serotonin norepinephrine reuptake inhibitor (SNRI), Venlafaxine com-
pared with other anti-depressants such as selective serotonin reuptake inhibitor 
(SSRI), tricyclic (TCA) or tetracyclic (TeCA) antidepressants. The remaining 6 articles 
analysed the CE of other anti-depressants not involving SNRI. The review showed 
conflicting outcomes due to heterogeneous study methodology. Ten out of 23 arti-
cles reported TCA/TeCA treatment to be most cost-effective treatment whereas six 
articles were in favour of SSRI and four articles favoured SNRI. cOnclusiOns: 
TCA/TeCA had comparable effectiveness compared to SNRI or SSRI. Despite the 
lower treatment cost with TCA/TeCA use, these treatments had higher AE rates 
compared to SNRI or SSRI, which were not taken into account during cost evaluation. 
This review identified several methodological issues and despite the calculation 
of ICER or CER, further studies are required to compare evidence on cost-effective 
anti-depressant treatment.
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Objectives: The Alzheimer diseases (AD) steadily increase with age in the early 
population. Considering that all over the world holds the fastest aging popula-
tion. According to the Alzheimer’s Association, cost spending is projected to be 
$2000 billion in 2050. The purpose of this study is to observe the cost effectiveness 
analysis (CEA) for the Alzheimer Drug. MethOds: The report was reviewed through 
report of ministry of welfare in Korea and clinical report data of paper about the 
Alzheimer drug inhibitors which are Aricept, Exelon and Reminyl. This analysis 
was used by CEA. Results: In Korea, the patients increased 84,000 in 2005 and 
262,000 in 2010. The patients increase 3.1 fold more increase. The total medical 
expenses $0.13 billion in 2005 and $0.81 billion in 2010. The total medical expense 
was 6.1 more increase. The per capita cost of treatment of Alzheimer diseases (AD) 
spends about 1.5$ in 2005 and 3.1$ in 2010. The per capita cost of treatment is 2 
times greater. Also,The medical fee of Aricept is $2, Exelon is $1.8 and Reminyl $1.3 
in Korea. The best drug of cost effectiveness is Reminyl and then Aricept. However, 
Exelon rejected within the cost effectiveness analysis, when anyone has a limited 
cost. cOnclusiOns: This revision strived to reduce the per capita cost of treat-
ment of AD. Most of all, it is critical not to delay care in Alzheimer patients in order 
to avoid increased direct medical costs. Therefore, in Alzheimer care, it is most 
critical to adequately check the symptom early discovery through the appropriate 
management techniques.
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Objectives: Elderly dementia results in progressive cognitive impairment and, 
eventually, the inability to living independently. The objective of this study was 
to assess the time required to provide care to patients with dementia according 
to their health state, and the consequences for the active population in China in 
2050. MethOds: The Chinese demographic forecasts for 2050 were put in balance 
with the need of estimated caregiving time needed by the dementia population. 
Demographic data, proportions of diagnosed and/or treated patients were provided 
by the China Alzheimer’s project Memory360. A Markov model was developed to 
estimate the average caregiver’s time needed per patient per day over 5 years, 
separately for treated and not treated patients. Results: The proportion of eco-
nomically active population aged between 15 and 59 in China in 2050 is estimated 
at 50% compared to the currently observed 70%.There will be approximately two 
workers for one elderly. It was found that untreated patient will require around 9.3 
hours per day compared to 6.7 hours per day required by a treated patient. It was 
estimated that there will be 21.6 million patients with dementia in China with only 
21.3% among them receiving treatment. More than 188 million hours per day will be 
needed to take care of Chinese dementia patients for around 690 million working 
people. cOnclusiOns: In the future, the situation in China will be dramatic due to 
the increase in the proportion of elderly and simultaneous reduction by around one 
fourth of the proportion of adults younger than 60. It was estimated that in average 
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Chemical (ATC-2012edition) System. A systematic approach was also used to 
compare national results of the current study to similar results of other coun-
tries. Results: More than 425 million prescriptions were reviewed. The total price 
of antidepressant prescription and dispensation was about 40 million and 210 mil-
lion US$ respectively. The most frequently prescribed medicines were nortriptyline, 
fluoxetine, and citalopram, which were accounted for 63% of all prescriptions. 87 
articles were retrieved from various databases and other sources after excluding the 
duplicated articles. 17 articles were screened by titles and abstracts. After excluding 
the non relevant studies, there were 6 articles remained which were eligible for full 
text assessment. cOnclusiOns: In compliance with the global trend, there was a 
growing tendency obviously observed towards prescribing SSRIs in Iran. In the face 
of rising burden of depression, on the one hand and the rising cost of medication 
and lack of funding resources on the other hand, we need to adopt strategies for 
promoting rational antidepressant medications use. These finding has important 
value for priority setting in planning and implementation of strategies for promot-
ing rational drug use.
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Objectives: To examine antidepressant prescription patterns in Japanese children 
and adolescents. MethOds: We conducted a cross-sectional survey during October 
2013 on outpatients, aged 19 or less, in 34 private mental clinics. Patients who were 
prescribed at least one antidepressant were analyzed in this report. Data on gen-
der, age, principal psychiatric diagnosis (based on ICD-10), and types and doses of 
psychotropic drugs were extracted. Results: The samples consisted of 137 males 
and 170 females. The average age (standard deviation) was 16.2 years (2.5). The 
mean length of psychiatric treatment was 23.6 months (23.3). The most frequent 
diagnostic category was neurotic disorders (F4; n= 113), followed by mood disor-
ders (F3; n= 73), disorders of psychological development (F8; n= 67), behavioral and 
emotional disorders (F9; n= 22), schizophrenic spectrum disorders (F2; n= 18), and 
other diagnoses (n= 14). Among the 19 antidepressants available in Japan, the pre-
scription rate of fluvoxamine (42.3%; n= 130) was the highest, followed by sertraline 
(17.6%), duloxetine (10.4%), escitalopram (9.8%), trazodone (6.5%), and paroxetine 
(5.5%). Tricyclic or tetracyclic antidepressants (TCAs) were prescribed in 35 patients 
(11.4%). Two or more antidepressants were prescribed concurrently in 27 (8.8%) of 
the 307 patients. Anxiolytics/hypnotics were concurrently prescribed in 126 (41.0%). 
Mood stabilizers were co-prescribed in 35 (11.4%). Antipsychotics were concurrently 
prescribed in 134 (43.6%), with a median dose of 100mg/d chlorpromazine equiva-
lent. cOnclusiOns: In Japan, although augmentation of antidepressant treatment 
seemed relatively popular with antipsychotics in adolescent patients, antipsychotic 
doses might be relatively low.
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Objectives: Many factors including patient, physician, medicine promotion and 
price affect prescribing of a medicine. The present study is aimed at showing the 
parameters that affect prescription writing and determine the effect of each of 
them on prescription process in Iran. MethOds: In order to investigate the effect 
of price, advertisement, gender, and age on the sales and prescribing process 
of three medicines, namely fluvoxamine, clopidrogrel and latanoprosta, pooling 
data method in econometrics (Panel data) was used. Results: We found that 
advertisement and medicine insurance coverage had significant positive effects 
on prescription of all three medicines whilst negative relationship were seen 
between increasing price and the frequency of prescription of a medicine. Besides, 
we found out that advertisement has a direct effect on raising the demand and 
prescription of the medicines. cOnclusiOns: Pharmaceutical companies need 
special attention to the index of physicians like age and sex in planning for sales 
and marketing of its products.
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Objectives: Stigmatization associated with mental illnesses could prevent schiz-
ophrenic and people with major depression to access to health care. Stigma often 
varies depending on social contexts. A survey in this subject was conducted first 
in Germany, then in France and finally in Tunisia. The objective of current study 
is to describe public beliefs and attitudes about schizophrenia, major depres-
sion and psychotropic drugs in Tunisia. MethOds: Three questionnaires were 
administered face-to-face to a representative sample of 1038 Tunisian people. 
415 persons answered a questionnaire on schizophrenia, 418 on major depression 
and 205 about psychotropic drugs. They were asked to address a validated ques-
tionnaire. Results: All 1038 questionnaires were fully completed. 38.8% (resp. 
26.8%) of people reported being not comfortable in presence of a schizophrenic 
patient (resp. major depression), while 33.7% (resp. 58.1%) reported they did. More 
than 89.9% (resp. 90.2%) felt the need to help people suffering from schizophrenia 
(resp. major depression), although 58.6% (resp. 43.3%) think that such patients 
are strange, and 29.6% (resp. 16.0%) think they are dangerous. 47.81% agree with 
the fact that psychotropic treatment helps people to better support the concerns 
chronic pain, while reducing their use of controlled medications. A larger follow-up 
study is needed to validate and expand on these preliminary findings.
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Objectives: The purpose of this study was to assess health-related quality of life 
(HRQoL) and economic burden among outpatients with major depressive disorder 
(MDD) in regards to achieving remission. MethOds: This was a nationwide cross-
sectional study. A total of 811 MDD patients over 18 years old were enrolled and 
each patient was allotted to one of three groups (1: 1: 1 ratio) as follow; new visit 
group (n= 287), remitted group (n= 235), and non-remitted group (n= 289). The 17-item 
Hamilton Depression Rating Scale (HAM-D) was used to assign patients to either 
remitted or non-remitted group. HRQoL was assessed with EuroQuol 5D (EQ-5D 
index score), EuroQuol Visual Analog Scale (EQ-VAS), and Quality of life Enjoyment 
and Satisfaction Questionnaire Short Form (Q-LES-Q-SF). To investigate the eco-
nomic burden of MDD patients, the total monthly costs (USD) were evaluated by sum 
of direct medical costs, direct non-medical costs (transportation and supplementary 
therapy), and indirect costs collected via patients interview. Indirect costs were 
measured by absenteeism and presenteeism utilizing the Korean version of World 
Health Organization Health and Work Performance Questionnaire (HPQ). Results: 
Non-remitted group showed statistically significant impairment of HRQoL as 
revealed by the results of EQ-5D index score, EQ-VAS, and Q-LES-Q-SF compared 
to remitted group (0.57±0.23 vs. 0.77±0.10, 50.9±20.34 vs. 72.5±16.59, 0.41±0.14 vs. 
0.58±0.16, respectively, p< 0.0001). Regarding direct medical costs, the non-remitted 
group incurred the highest costs compared to other groups (p< 0.0286). As of the 
indirect costs, remitted group demonstrated significant improvement in produc-
tivity when compared with other groups (p< 0.0001). Total monthly costs were the 
highest in non-remitted group (1187±857.8) compared to remitted group (766±684.5) 
and new visit group (1063±773.1), (p< 0.0001). cOnclusiOns: Non-remitted MDD 
patients suffer from both lower HRQoL and higher economic burden compared 
with remitted group and new visit group. These results suggest the importance of 
achieving remission in Korean MDD patients.
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Objectives: To determine the prevalence and predictors of cognitive impairment 
among older residents of nursing homes in the state of Penang, Malaysia. MethOds: 
This multi-centred cross-sectional study was conducted in two phases over a six-
month period at four non-governmental nursing facilities in Penang, Malaysia. 
Older residents (≥ 65 years old) who were taking at least one medication and had 
not been previously diagnosed with dementia were included. Demographic and 
clinical data were collected through direct interviews and the review of medical 
records. Cognitive screening was performed using the Mini-Cog at baseline. Health 
Related Quality of Life (HRQOL) was assessed at baseline and after a three-month 
interval using the EuroQol (EQ-5D) and EQ Visual Analogue Scale (VAS). Results: 
The study included 211 residents with mean (SD) age of 77.7 (7.0) years and majority 
female residents, 128 (60.7%). Mini-Cog identified 129 (61%) residents with cognitive 
impairment. The three most common co-morbidities among the sample popula-
tion were hypertension (71.1%), diabetes mellitus (27.1%) and cerebral vascular 
disease (12.3%). Logistic regression analysis shown that longer formal education 
of more than six years (OR = 2.81, p = 0.007, 95% CI [0.167-0.757]) and inability to 
self-administer medications (OR = 3.29, p < 0.001, 95% CI [0.156-0.594]) significantly 
predicted cognitive impairment based on Mini-Cog score ≤ 2. However, Mini-Cog 
was not significantly associated with changes in HRQOL at three months follow-
up. cOnclusiOns: We found a high prevalence of possible cognitive impairment 
among nursing home residence who had not been previously diagnosed, especially 
those who were unable to self-administer their medications. The length of formal 
education can be deceptive. Therefore, more vigilant screening should be performed 
for early detection and proper intervention of dementia although HRQOL is not 
affected by poor scoring in Mini-Cog.
Mental HealtH – Health care use & Policy Studies
PMH32
PatteRn Of antidePReSSant utilizatiOn and cOSt in iRan fROM 2007-
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Objectives: To assess the prescribing and usage pattern of antidepressant medi-
cations and the impact of their cost from 2007 to 2011 in Iran and to compare the 
results to other countries. MethOds: A cross-sectional study was carried out on 
physicians’ prescription data based on the claims that the pharmacies submitted 
electronically to the insurers during 5 years from 2007 to 2011. Data related to 
dispensing of antidepressant were obtained from the official databank of national 
regulatory authority. Drugs were classified according to the Anatomic Therapeutic 
